Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, Jochen Buechner...
https://pubmed.ncbi.nlm.nih.gov/29385370/Actively Recruiting
Led by Dr. Zaineb Akram · Updated on 2026-07-10
10
Participants Needed
1
Research Sites
N/A
Total Duration
Acute lymphoblastic leukemia ALL is the most common cancer in children and the second most frequent acute leukemia in adults. B-cell ALL makes up about 85% of ALL cases. In Pakistan, ALL is the most common blood cancer treated at major centers. While initial chemotherapy can lead to remission in most children, relapse rates remain significant, and adults generally have poorer outcomes. For patients with relapsed or refractory disease, new treatment options are needed due to limitations of standard therapies and transplants. This study evaluates an investigational autologous anti-CD19 CAR-T cell therapy developed and manufactured on-site at AFBMTC in Pakistan. The treatment involves collecting a patients own T cells, modifying them to target CD19 on leukemia cells, and then infusing them after chemotherapy to reduce leukemia burden. The therapy uses a lentiviral vector and an automated bioreactor system to produce the CAR-T cells. This pilot trial aims to assess the safety, feasibility, and early effectiveness of this approach in patients aged 5 to 50 years with relapsed or refractory B-cell ALL. Participants will undergo leukapheresis to collect T cells, followed by CAR-T cell manufacturing and infusion after receiving lymphodepleting chemotherapy. Researchers will monitor participants for safety and treatment effects over one year after infusion. Assessments include blood tests, bone marrow evaluation, and performance status checks. Long-term follow-up for up to 15 years will track gene therapy safety. The study measures safety and feasibility as its primary outcomes and involves regular clinical visits and monitoring throughout the treatment and follow-up periods.
CONDITIONS
CAR-T Cell Therapy for ALL
N
Nadia Sial, Ph.D
M
Maryam Khan, MBBS, MRCP(UK), FCPS (Cl Haem)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Dr. Zaineb Akram
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Variable, typically a few weeks
Participants undergo leukapheresis to collect T cells, which are then processed and modified to produce CAR-T cells using specialized equipment.
Multiple visits during collection and manufacturing
Duration - Short period around infusion
Participants receive chemotherapy to reduce immune cells followed by a single infusion of the CAR-T cells targeting their leukemia.
Several visits for chemotherapy and infusion
Duration - Up to 15 years
Participants are monitored for safety, treatment effects, and long-term gene therapy safety through clinical evaluations and laboratory tests for up to one year and beyond.
Regular follow-up visits scheduled
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Shannon L Maude, Theodore W Laetsch, Jochen Buechner...
https://pubmed.ncbi.nlm.nih.gov/29385370/Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li...
https://pubmed.ncbi.nlm.nih.gov/28924019/Daniel W Lee, Bianca D Santomasso, Frederick L Locke...
https://pubmed.ncbi.nlm.nih.gov/30592986/Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett...
https://pubmed.ncbi.nlm.nih.gov/29226797/Stephan A Grupp, Michael Kalos, David Barrett...
https://pubmed.ncbi.nlm.nih.gov/23527958/Dr. Zaineb Akram
Lead Sponsor